Complaints Outcomes

Search

Search Results

Search Again
Lum, King Cheong (Steven) (Jan 1, 2018)

King Cheong (Steven) Lum has completed a term of suspension which ended on December 31, 2017, and is eligible for reinstatement of registration. Until December 31, 2022, he will be limited from being a manager, director or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor.


January 1, 2017
(January 1, 2018 – Registration reinstated)

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with King Cheong (Steven) Lum (the “Registrant”) to suspend his registration as a pharmacist for 365 consecutive days, from January 1, 2017 to December 31, 2017.

In or about April 2016, while pharmacy manager, director, and owner of a pharmacy, the Registrant discovered discrepancies between the on-hand quantities and computer quantities of 47 individual molecules of narcotic and controlled drugs and 21 individual molecules of benzodiazepines at the pharmacy. The most significant discrepancies were 165,998 tablets of Ratio-Oxycocet (oxycodone/acetaminophen 5mg/325mg), 1,030 tablets of Ratio-Lenoltec No. 3 (acetaminophen/caffeine/codeine 300mg/15mg/30mg), and 17,353 tablets of Mylan-Alprazolam 2mg. The Registrant had not noticed the discrepancies for many months until April 2016, and therefore the discrepancies had not been reported to Health Canada as required.

After an investigation, it was substantiated that while the Registrant was pharmacy manager, director, and owner of a pharmacy, he failed to maintain a standard of practice of the pharmacy profession and contravened the relevant provincial and federal legislation with respect to the following:

  • Management of inventory of narcotics, controlled drugs and targeted substances under his control to prevent loss or theft, including failure to count and reconcile all narcotics, controlled drugs and targeted substances at least every three months as required by Professional Practice Policy #65;
  • Failure to maintain records of purchases, sales and remaining inventory for narcotics and other controlled drugs;
  • Failure to make timely reports of losses of narcotics and other controlled drugs to Health Canada; and
  • Failure to adhere to s. 43 of the Narcotic Control Regulations, s. G.03.012 of the Food and Drug Regulations, and s. 7(1)(b) of the Benzodiazepines and Other Targeted Substances Regulations, in that he failed to take all reasonable steps that were necessary to protect narcotics, controlled drugs and targeted substances on the premises or under his control against loss or theft or to take steps necessary to ensure their security, including failure to count and reconcile narcotics, controlled drugs and targeted substances at least every three months.

The Inquiry Committee considered that the Registrant’s serious lack of judgment constituted professional misconduct.

Prior to reinstatement of his registration following the suspension period, the Registrant will be required to:

  • thoroughly review relevant legislative requirements and to sign a Declaration acknowledging his understanding of and compliance with the legislative requirements;
  • meet with the Inquiry Committee to discuss his reflections on his conduct and what he has learned;
  • successfully pass the College’s Jurisprudence Exam; and
  • pay a $30,000 fine.

The Registrant will also be limited from being a manager, director, or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor for a period of five years from the date that his suspension ends (commencing December 31, 2017).

The Inquiry Committee considers this Agreement necessary to protect the public, as well as send a clear message to the profession that the College does not tolerate this type of conduct.


May 20, 2016
(January 1, 2017 – Registration suspended)

The Inquiry Committee, pursuant to section 35(1) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant King Cheong (Steven) Lum, effective May 20, 2016, pending completion of an investigation of his pharmacy practice. Until further notice, Mr. Lum has the following limits and conditions on his practice:

  1. He will be restricted from the following roles in his practice:

    1. Be an owner or manager of a pharmacy;
    2. Be a director of a corporation that owns a pharmacy; and
    3. Act as a preceptor;

     

  2. He will be restricted from doing the following in relation to narcotic and controlled drugs and substances:

    1. Placing orders; 
    2. Signing wholesaler/manufacturer invoices confirming receipt of orders, or have any sort of signing authority relating to such orders; and
    3. Conducting counts and/or reconciliation of inventory;

     

  3. Prior to the commencement of new employment at any pharmacy, he will inform every manager and employer of the pharmacy in which he gains employment of the limits and conditions on his license pursuant to this order, and will ensure that the pharmacy manager and employer submits a written statement to the College declaring their awareness of the limits and conditions and how the limits and conditions will be accommodated in the pharmacy.

The registrant was the pharmacy manager, director, and owner of a pharmacy, and did not fulfill the responsibilities of a pharmacy manager, director, and owner to operate a pharmacy that met legislative and practice standards. He had not established and/or enforced policies and procedures for inventory management and security and storage of narcotic and controlled drugs, enabling a grossly large quantity of narcotic and controlled medication to be lost and/or taken from the pharmacy and potentially diverted, causing potential harm to the public.

Lam, Alexis Vanessa (Dec 8, 2017)

Alexis Vanessa Lam has satisfied all the terms of an agreement reached with the Inquiry Committee dated May 9, 2017.  Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. 


May 9, 2017
(December 8, 2017 - Limits and conditions removed)

The Inquiry Committee, pursuant to section 35(1)(a) of the Health Professions Act, R.S.B.C. 1996, c. 183, for the purposes of public protection, has imposed limits and conditions on the practice of registrant Alexis Vanessa Lam, pending completion of an investigation of her pharmacy practice. Until further notice, Ms. Lam has the following limits and conditions on her practice:

  1. Effective May 9, 2017, she will be restricted from doing the following in relation to narcotic and controlled drugs and substances:
    1. Placing and receiving orders; and
    2. Signing wholesaler/manufacturer invoices confirming receipt of orders, or have any sort of signing authority relating to such orders.

Ms. Lam has not demonstrated that she has fulfilled her responsibility as a registrant to take reasonable steps to protect narcotic and controlled drugs against loss in or from the pharmacy where she works. In addition, she has not kept accurate records regarding all purchases and sales of narcotic and controlled drugs. This has enabled a large quantity of narcotic and controlled drugs at the pharmacy to be unaccounted for, causing potential harm to the public.

Pharmacist Registrant 4 (Nov 23, 2017)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend the registration as a pharmacist effective November 23, 2017. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.


February 20, 2015
(November 23, 2017 - Registration Suspended)

Pharmacist Registrant 4 has satisfied the terms of an agreement reached with the Inquiry Committee dated April 1, 2010. Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act.


April 1, 2010
(February 20, 2015 - Limits and conditions removed)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to place limits and/or conditions on his registration as a pharmacist effective April 1, 2010. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act.

Robertson, Chadwick Aaron (Nov 22, 2017)

On a series of occasions during 2015, Chadwick Aaron Robertson (the “Registrant”) made comments to LC, an individual posing as an athlete, about the use of banned drugs and their suitability for the purpose. The Registrant provided LC a training protocol that was never put into operation. Unbeknownst to the Registrant, LC was part of an “undercover” investigation and the Registrant’s meetings and other dealings with LC were being videotaped. An edited version of the footage was ultimately broadcast over the Internet.  The College considers, and the Registrant concedes, that this conduct reflected negatively on the Registrant and the profession of pharmacy in British Columbia. It constitutes professional misconduct, a serious matter pursuant to section 26 of the Health Professions Act

For the above conduct, pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached a consent agreement with the Registrant for the following terms and undertakings:

  • That the Registrant’s registration as a Full Pharmacist be suspended for a period of six (6) months, to commence on November 22, 2017;
  • That the Registrant pay a $10,000.00 fine to the College no later than November 22, 2018;
  • That a letter of reprimand be placed permanently on the College’s register;
  • That he appear before a panel of the Inquiry Committee for a verbal reprimand;
  • That he successfully complete the ProBE Program on Professional/Problem-Based Ethics for healthcare professionals no later than November 22, 2018; and
  • That he thoroughly review relevant legislation and complete the College’s Code of Ethics Educational Tutorial and sign declarations acknowledging his understanding and compliance with legislative and ethical requirements.
Pharmacist Registrant 33 (Sep 11, 2017)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an agreement with the pharmacist registrant to not engage in the practice of pharmacy. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to section 39.3(4) of the Health Professions Act.

Yan, Cheryl Qian (Aug 10, 2017)

The Inquiry Committee has deemed Cheryl Qian Yan eligible for reinstatement of her registration, as she has completed and passed the Canadian Pharmacy Practice Programme pursuant to the terms of the Agreement reached on February 24, 2015.

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached a revised Agreement with Ms. Yan, whereby after the reinstatement of her registration, for a specified period of time she must abide by certain limits and conditions on her practice, and she must disclose these limits and conditions to future employers. These limits and conditions include (but are not limited to):

  • Working under direct supervision of a BC pharmacist in good standing;
  • Not working alone;
  • Not being a supervisor, manager, and/or preceptor;
  • Informing employers and the College in writing regarding any medication-related incidents and/or errors that she is involved in; and
  • Notifying the College in writing regarding any changes in employment.

The Inquiry Committee considers these actions necessary to protect the public.


February 24, 2015
(August 10, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with Ms. Cheryl Qian Yan where she has voluntarily suspended her pharmacy licence until she has completed and passed the Canadian Pharmacy Practice Programme, and then she will be subject to placing limits and/or conditions on her practice as follows depending on the setting:

  1. If a Hospital Pharmacy or Affiliated Hospital setting:

     

    1. Ms. Yan must work under the direct supervision of a BC licensed pharmacist for a period to three (3) months full time equivalent; where with the current contract, a full time week is 37.5 hours with 7.5 hour work days; and

       

    2. Ms. Yan must not work in a hospital pharmacy or an affiliated pharmacy setting as a pharmacist in a sole practitioner capacity. This means that Ms. Yan must not supervise anyone, direct work, be a manager or a preceptor or pharmacist in charge, for a period to three (3) months full time equivalent; where with the current contract, a full time week is 37.5 hours with 7.5 hour work days.

     

  2. If a Community Pharmacy setting:

     

    1. Ms. Yan will be restricted to process no more than sixty (60) prescriptions daily, within an eight (8) hour shift for a period equivalent to six (6) months full time;

       

    2. Ms. Yan must work under the direct supervision of a BC licensed pharmacist for a period equivalent to three (3) months full time, based on 8 hours per day / 40 hours per week or a total of 480 hours;

       

    3. Ms. Yan must not work in a community pharmacy as a pharmacist in a sole practitioner capacity. This means that Ms. Yan must not supervise anyone, direct work, be a manager or a preceptor or pharmacist in charge, for a period equivalent to three (3) months full time, based on 8 hours per day /40 hours per week or a total of 480 hours; and

       

    4. Ms. Yan will be subject to a practice audit in a community pharmacy of which she must complete and pass during the above six (6) months period mentioned in the above paragraphs 2 (b) and 2 (c).

The Inquiry Committee considers these actions necessary to protect the public.

Ratansi, Elishah (May 13, 2017)

Elishah Ratansi has satisfied terms of an agreement reached with the Inquiry Committee on July 6, 2015. Limits and conditions on the Elishah Ratansi’s registration as a pharmacist have now been removed.


August 12, 2016
(May 13, 2017 – Limits and conditions removed)

The Registration Committee has reinstated Ms. Ratansi’s registration as a Full/Active Pharmacist, effective August 12, 2016. Pursuant to a Consent Agreement signed on July 6, 2015, Ms. Ratansi agrees to the following limits and conditions on her practice, effective August 12, 2016:

  1. Prohibition from acting as a director for 9 months upon return to practice as a Full/Active Pharmacist; and
  2. Prohibition from acting as a pharmacy manager for 9 months upon return to practice as a Full/Active Pharmacist.

July 6, 2015
(August 12, 2016 – Registration reinstated)

Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached a Consent Agreement with Ms. Elishah Ratansi, effective July 6, 2015. This was the result of investigations conducted on a pharmacy under the management of Ms. Ratansi where several practice violations were allegedly found.  Also in the course of her employment as a pharmacist at the pharmacy in question, an illegal delivery scheme for transporting controlled substances was allegedly implemented by the management and pharmacy staff.  In light of the Inquiry Committee’s investigation and findings, Ms. Ratansi voluntarily placed her licence on non-practising status since January 1, 2015.  She agreed to the following terms in the Consent Agreement, among others:

  1. Suspension of registration as a pharmacist for six consecutive months, effective January 1, 2015. 
  2. Prohibition from acting as a director for 9 months upon return to practice as a Full/Active Pharmacist,
  3. Prohibition from acting as a pharmacy manager for 9 months upon return to practice as a Full/Active Pharmacist,
  4. Notification about this suspension will be published on the College website, pursuant to s. 39.3 of the Health Professions Act.

In the same Consent Agreement, Ms. Ratansi also agreed that she will not repeat the alleged conduct and to thoroughly review the legislation of which she was in breach.

Pharmacist Registrant 30 (May 1, 2017)

The Inquiry Committee, pursuant to section 36 of the Health Profession Act, has reached a new revised Agreement with the pharmacist registrant, whereby the Registrant consented to undertakings that include, but are not limited to:

  1. Complying with any and all treatment plans as recommended by the Registrant’s medical providers, including but not limited to the following:

    1. Regular and consistent attendance to the Registrant’s meetings with mental health team; and
       
    2. Adherence to medication regimen;

  2. Voluntarily stop working as a pharmacist and self-report to the College in the event that the Registrant’s medical condition may hinder performance and/or fitness to practice as a pharmacist;

The name of the Registrant has been withheld in accordance with section 39.3(4)(a) of the Health Professions Act for the purposes of not identifying the personal health information of the Registrant respecting the condition. The Inquiry Committee is satisfied that the undertakings will protect the public.


February 8, 2017
(May 1, 2017 - Limits and Conditions Revised)

The Inquiry Committee has reinstated pharmacist registrant’s registration which had previously been suspended for an indefinite period on December 23, 2016. Pursuant to section 36 of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the Registrant consented to undertakings involving regular monitoring for fitness to practice pharmacy. The undertakings include, but are not limited to:

  1. Complying with any and all treatment plans as recommended by the Registrant’s medical providers, including but not limited to the following:

    1. Regular and consistent attendance to meetings with the Registrant’s mental health team; and
       
    2. Adherence to medication regimen;

  2. That after returning to work in pharmacy setting, on every shift of employment at any pharmacy, the Registrant will work alongside another pharmacist in good standing at all times;

     

  3. That prior to the commencement of new employment at any pharmacy, the Registrant shall disclose to the pharmacy manager the limits and conditions of this Consent Agreement and ensure that arrangements are made in the pharmacy operations to accommodate the said limits and conditions:

    1. The Registrant must ensure that the pharmacy manager and/or employer with whom the Registrant secures employment submits a written statement to the College declaring:

      1. their awareness of the limits and conditions in; and
         
      2. their obligation to contact the College if they have questions or concerns about the Registrant’s practice. This statement must be received within 48 hours of any change of employment and/or 48 hours of any change in pharmacy manager/employer.

    2. The Registrant must inform a Complaints Officer in writing or via email of  places of employment as a pharmacist and report any changes of the location of employment within 72 hours of such change.

December 23, 2016
(February 8, 2017 – Registration reinstated)

The Inquiry Committee, pursuant to section 36 of the Health Professions Act, has reached an Agreement with the pharmacist registrant to suspend registration as a pharmacist, effective December 23, 2016. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant's name has been withheld, pursuant to s. 39.3(4) of the Health Professions Act.

Drapeau , Tyler Joshua (Apr 20, 2017)

Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) reached a consent agreement with Tyler Joshua Drapeau (the “Registrant”) to suspend his registration as a pharmacist for a period of six months, from April 20, 2017 to October 20, 2017.

After an investigation, the Registrant admitted to practicing outside of his scope by prescribing and dispensing multiple medications to himself and others without a valid prescription. The Registrant prescribed medication to himself over 30 times without any prescription from a physician and inappropriately dispensed medications to himself on various other occasions. In relation to prescribing medications to others, the Registrant prescribed and dispensed azithromycin 26 times without a valid prescription, atavaquone proguanil two times without a valid prescription and doxycycline without a valid prescription. The Registrant listed the wrong prescriber on a prescription and conducted improper adaptations and emergency refills, each not in compliance with the Professional Practice Policies.

The Inquiry Committee determined that the Registrant breached the Code of Ethics – Detailed, Standard 1(b) which states that registrants practice only within the scope of their education, training and competence, Further, the Code of Ethics – Conflict of Interests Standards, Standard 2(e) very narrowly defines that registrants may only dispense medications to themselves in an emergency situation or when another registrant is not readily available.

The Inquiry Committee determined that the Registrant acted outside of scope, that he was not trained to prescribe any of the medications at issue, and that pharmacists in British Columbia do not have authority under legislation or the Code of Ethics to prescribe to themselves.

The Inquiry Committee determined that the Registrant engaged in professional misconduct and unethical conduct in relation to the unauthorized prescribing and dispensing practices, taking into account the gravity of the contraventions listed above and that the volume of practice deficiencies constituted a serious matter.

Prior to reinstatement, the Registrant must:

  • Appear before a panel of the Inquiry Committee for a verbal reprimand;
  • Successfully complete and pass the College Jurisprudence Exam;
  • Submit a fine of $5,000;
  • Thoroughly review the relevant legislation and sign a declaration acknowledging his understanding and rigid compliance with those legislative requirements.

The Registrant may not act as a pharmacy manager for a period of three years following reinstatement.

A letter of reprimand will be permanently placed on the College register and the College may disclose its contents in response to inquiries regarding the status of the Registrant’s registration. The Inquiry Committee considers this Agreement necessary to protect the public.

Asaria, Alnazir (Mar 12, 2017)

​Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) reached a consent agreement with Alnazir Asaria (the “Registrant”) to suspend his registration as a pharmacist until he successfully completes and passes the College Jurisprudence Exam.

Following investigation, the Inquiry Committee determined that between January 1, 2011 and December 31, 2012, the Registrant, while pharmacy manager and owner of a pharmacy, practiced in contravention of the Bylaws to the Health Professions Act, Schedule F Part 1 Community Pharmacy Standards of Practice (the “Standards of Practice”) and the Bylaws to the Pharmacy Operations and Drug Scheduling Act (the “Bylaws to the PODSA”).

Specifically, the Registrant engaged in deficient practice relating to:

  • Prescriptions filled in excess of authorized quantity;
  • Prescriptions filled after the expiry date;
  • Incomplete prescriptions missing quantity, dose or directions;
  • Prescriptions filled under the wrong prescriber;
  • Methadone prescriptions released to patients without complete and signed part-fill or witnessed ingestion logs;
  • Methadone given as carries without prescriber authorization;
  • Methadone prescriptions without adequate documentation including lack of Controlled Prescription Program (“CPP”) hardcopy prescription, CPP prescriptions without patient signature;
  • Methadone dispensed under incorrect DIN;
  • Prescription adaptation without adequate rationale or documentation;

The Inquiry Committee determined that the Registrant breached the Standards of Practice for each of the allegations listed and that the cumulative weight of the contraventions represent a serious matter which requires substantial remediation.

Prior to reinstatement of his registration, the Registrant must:

  • Thoroughly review the relevant legislation and sign a Declaration acknowledging his understanding of and rigid compliance with those legislative requirements;
  • Successfully complete and pass the College Jurisprudence Exam;

A Letter of Reprimand will be permanently placed on College Register and the College may disclose its contents in response to inquiries regarding the status of the Registrant’s registration.

The Inquiry Committee determined that the cumulative weight of each of the practice deficiencies demonstrated the Registrant’s disregard for his professional obligations and general sloppy practice. The sheer volume of practice deficiencies and breached practice standards demand a serious response to bring the Registrant’s practice into compliance with the governing legislation. The Inquiry Committee considers this agreement necessary to protect the public.

Pages